

This listing of claims will replace all prior versions, and listings, of the claims in the application:

**Listing of Claims:**

Claims 1-43 (Cancelled)

Claim 44 (Currently Amended) A method for treating an allergic condition in a subject, comprising administering a pharmaceutically effective amount of a therapeutic agent to the subject, said therapeutic agent comprising a molecule having at least a first segment competent for importation of said molecule into mast cells in vivo, and a second segment for having an anti-allergic effect within said mast cells, said first segment being joined to said second segment through a linker, whereby the complex molecule is capable of exerting its anti-allergic effect in vivo The method of claim 30, and wherein said second segment is a peptide taken from the C terminal sequence of G $\alpha_t$ .

Claim 45 (Currently Amended) The method of claim 30 44, wherein said molecule is a peptide having an amino acid sequence AAVALLPAVLLALLAPKENLKDGLF (SEQ ID NO:12).

Claim 46 (Currently Amended) The method of claim 30 44, wherein said therapeutic agent further comprises a second molecule, said second molecule being a peptide having an amino acid sequence AAVALLPAVLLALLAPKNNLKECGLY (SEQ ID NO:7).

Claims 47-49 (Cancelled)

Claim 50 (Currently Amended) A method for treating an allergic condition in a subject, comprising administering a pharmaceutically effective amount of a therapeutic agent to the subject, said therapeutic agent comprising a molecule having at least a first segment competent for importation of said molecule into mast cells in vivo, and a second segment for having an anti-allergic effect within said mast cells, said first segment being joined to said second segment through a linker, whereby the complex molecule is capable of exerting its anti-allergic effect in vivo The method of claim 43, wherein said second segment is a peptide having an amino acid

sequence AAVALLPAVLLALLAPKNNLKECGLY (SEQ ID NO:7), and cyclic derivatives thereof, and wherein the molecule further comprises cyclization between lysine at position 17 and the C terminus of the peptide.

Claim 51 (Cancelled)

Claim 52 (New) The method of claim 44, wherein the allergic condition is selected from the group consisting of nasal allergy, an allergic reaction in an eye of the subject, an allergic reactions in the skin of the subject, acute urticaria, psoriasis, psychogenic or allergic asthma, interstitial cystitis, bowel diseases, migraines and multiple sclerosis.

Claim 53 (New) The method of claim 44, wherein administration of said therapeutic agent is performed by topical administration.

Claim 54 (New) The method of claim 53, wherein said topical administration is to the eye, the skin or to a mucus membrane of the subject.

Claim 55 (New) The method of claim 44, wherein administration of said therapeutic agent is performed by inhalation or intranasal administration.

Claim 56 (New) The method of claim 44, wherein administration of said therapeutic agent is performed by oral or systemic parenteral administration.

Claim 57 (New) The method of claim 44, wherein said second segment has said anti-allergic effect by at least significantly reducing degranulation of said mast cells.

Claim 58 (New) The method of claim 44, wherein said first segment is selected from the group consisting of a peptide, peptidomimetic or a polypeptide.

Claim 59 (New) The method of claim 44, wherein said linker is a covalent bond.

Claim 60 (New) The method of claim 59, wherein said covalent bond is a peptide bond.

Claim 61 (New) The method of claim 44, wherein said molecule is a peptide having an amino acid sequence VTVLALGALAGVGVGKENLKDCGLF (SEQ ID NO:11).

Claim 62 (New) The method of claim 44, wherein said molecule is a peptide having an amino acid sequence RQPKIWFPNRRKPWKKENLKDCGLF (SEQ ID NO:13).